PuriCore Plc Result of General Meeting (8959L)

TIDMPURI

RNS Number : 8959L

PuriCore Plc

06 October 2016

PuriCore plc

("PuriCore" or the "Company")

Result of General Meeting

6 October 2016 - PuriCore plc (AIM: PURI), the emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announced on 20 September 2016 it had agreed to sell the Group's Supermarket Retail Business, subject to Shareholder approval and other customary requirements, to Chemstar Corp.

The Company is pleased to announce that the Resolution, as set out in the notice of general meeting contained within the Circular to Shareholders, approving the Disposal was duly passed at the general meeting held today. Completion of the Disposal is expected tomorrow and a further announcement will be made in due course.

Enquiries:

 
                                         [phone] 
 PuriCore plc                             1000 
 Alex Martin, Chief Executive Officer 
 Marella Thorell, Chief Financial 
  Officer and Chief Operating Officer 
 
                                         [phone] 
 FTI Consulting                           1000 
 Simon Conway / Mo Noonan 
 
 N+1 Singer (Nominated Adviser and       [phone] 
  Broker)                                 3000 
 Aubrey Powell / Jen Boorer 
 

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014 (MAR).

Unless otherwise indicated, capitalised terms in this announcement have the same definition as in the Circular.

About PuriCore

PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated a drug development programme, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology, Ophthalmology and potentially rare diseases. For more details, go to the Company's website: www.puricore.com

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMDMMGGGVZGVZM

(END) Dow Jones Newswires

October 06, 2016 06:43 ET (10:43 GMT)